These studies suggest that Kcnh2 plays a protective role in SCID by reducing cardiomyocyte apoptosis through AKT/FOXO3A/BIM pathways, providing rationale for Kcnh2 as a promising candidate target in SCID. Here, FOXO3 is linked to severe combined immunodeficiency.